Current and future perspectives in the management and treatment of colorectal cancer

被引:1
作者
Romero-Zoghbi, Sigfredo E. [1 ]
Krumina, Evita [2 ]
Lopez-Campos, Fernando [3 ,4 ]
Counago, Felipe [5 ]
机构
[1] GenesisCare Talavera Reina, Dept Radiat Oncol, Toledo 45600, Spain
[2] GenesisCare Guadalajara, Dept Radiat Oncol, Guadalajara 19004, Spain
[3] Hosp Univ Ramon & Cajal, Dept Radiat Oncol, Madrid 28034, Spain
[4] GenesisCare Hosp Univ Vithas Madrid Milagrosa, Dept Radiat Oncol, Madrid 28010, Spain
[5] GenesisCare San Francisco Asis Univ Hosp, Dept Radiat Oncol, Calle Joaquin Costa 28, Madrid 28002, Spain
关键词
Colorectal cancer; Metastatic colorectal cancer; Total neoadjuvant therapy; Chemoradiotherapy; Colon surgery; Rectal surgery; Chemotherapy; Immunotherapy; RADIATION-THERAPY; RECTAL-CANCER; OPEN-LABEL; CHEMOTHERAPY; CETUXIMAB; SURGERY; IMPACT;
D O I
10.5306/wjco.v16.i2.100807
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this editorial, we reviewed the article by Fadlallah et al that was recently published in the World Journal of Clinical Oncology. The article provided a comprehensive and in-depth view of the management and treatment of colorectal cancer (CRC), one of the leading causes of cancer-related morbidity and mortality worldwide. The article analyzed the therapeutic modalities and their sequencing, focusing on total neoadjuvant therapy for locally advanced rectal cancer. It highlighted the role of immunotherapy in tumors with high microsatellite instability or deficient mismatch repair, addressing recent advances that have improved prognosis and therapeutic response in localized and metastatic CRC. Innovations in surgical techniques, advanced radiotherapy, and systemic agents targeting specific mutational profiles are also discussed, reflecting on how they revolutionized clinical management. Circulating tumor DNA has emerged as a promising tool for detecting minimal residual disease, prognosis, and therapeutic monitoring, solidifying its role in precision oncology. This review emphasized the importance of technological and therapeutic advancements in improving clinical outcomes and personalizing CRC treatment.
引用
收藏
页数:10
相关论文
共 50 条
[1]   Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up [J].
Agolli, Linda ;
Bracci, Stefano ;
Nicosia, Luca ;
Valeriani, Maurizio ;
De Sanctis, Vitaliana ;
Osti, Mattia Falchetto .
CLINICAL COLORECTAL CANCER, 2017, 16 (01) :58-64
[2]   Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer [J].
Alvarez, Janet A. ;
Shi, Qian ;
Dasari, Arvind ;
Garcia-Aguilar, Julio ;
Sanoff, Hanna ;
George, Thomas J. ;
Hong, Theodore ;
Yothers, Greg ;
Philip, Philip ;
Nelson, Garth ;
Al Baghdadi, Tareq ;
Alese, Olatunji B. ;
Zambare, Wini ;
Omer, Dana ;
Verheij, Floris S. ;
Bercz, Aron ;
Kim, Min Jung ;
Buckley, James ;
Williams, Hannah ;
George, Manju ;
Garcia, Reese ;
Gallagher, Phuong ;
O'Reilly, Eileen M. ;
Meyerhardt, Jeffrey A. ;
Crawley, Jamie ;
Shergill, Ardaman ;
Horvat, Natally ;
Romesser, Paul B. ;
Hall, William ;
Smith, J. Joshua .
BMC CANCER, 2024, 24 (01)
[3]   Effect of laparoscopic surgery on the risk for surgical site infections in colorectal resection: results from the Health Insurance Review & Assessment Service Database [J].
An, Sang Hyun ;
Youn, Mi Kyong ;
Kim, Ik Yong .
ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) :315-323
[4]   Protocol amendment for ENSEMBLE study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neo-adjuvant therapy in patients with locally advanced rectal cancer-Changing the irinotecan dosage [J].
Ando, Koji ;
Watanabe, Jun ;
Kagawa, Yoshinori ;
Bando, Hideaki ;
Kotani, Daisuke ;
Suwa, Yusuke ;
Nishizawa, Yujiro ;
Takahashi, Yusuke ;
Matsuhashi, Nobuhisa ;
Suwa, Hirokazu ;
Sugiyama, Masahiko ;
Kanemitsu, Yukihide ;
Oki, Eiji ;
Uemura, Mamoru ;
Yokota, Mitsuru ;
Tsuboyama, Takahiro ;
Oba, Koji ;
Kato, Takeshi ;
Yoshino, Takayuki .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) :TPS99-TPS99
[5]   Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Argiles, G. ;
Tabernero, J. ;
Labianca, R. ;
Hochhauser, D. ;
Salazar, R. ;
Iveson, T. ;
Laurent-Puig, P. ;
Quirke, P. ;
Yoshino, T. ;
Taieb, J. ;
Martinelli, E. ;
Arnold, D. .
ANNALS OF ONCOLOGY, 2020, 31 (10) :1291-1305
[7]   Enhancing visualization and guidance in general surgery: a comprehensive and narrative review of the current cutting-edge technologies and future perspectives [J].
Brollo, Pier Paolo ;
Bresadola, Vittorio .
JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (02) :179-185
[8]   Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: A systematic review and meta-analysis [J].
Burbach, Johannes Peter Maarten ;
den Harder, Annemarie Maria ;
Intven, Martijn ;
van Vulpen, Marco ;
Verkooijen, Helena Marieke ;
Reerink, Onne .
RADIOTHERAPY AND ONCOLOGY, 2014, 113 (01) :1-9
[9]   ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in primary locally advanced rectal cancer [J].
Calvo, Felipe A. ;
Sole, Claudio V. ;
Rutten, Harm J. ;
Poortmans, Philip ;
Asencio, Jose M. ;
Serrano, Javier ;
Aristu, Javier ;
Roeder, Falk ;
Dries, Wim J. .
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 25 :29-36
[10]   FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer [J].
Casak, Sandra J. ;
Horiba, M. Naomi ;
Yuan, Mengdie ;
Cheng, Joyce ;
Lemery, Steven J. ;
Shen, Yuan Li ;
Fu, Wentao ;
Moore, Jason N. ;
Li, Yangbing ;
Bi, Youwei ;
Auth, Doris ;
Fesenko, Nataliya ;
Kluetz, Paul G. ;
Pazdur, Richard ;
Fashoyin-Aje, Lola A. .
CLINICAL CANCER RESEARCH, 2023, 29 (21) :4326-4330